Acitrin-L Tablet: Each film coated tablet contains Levocetirizine Dihydrochloride INN 5 mg.
Acitrin-L Oral solution: Each 5 ml contains Levocetirizine Dihydrochloride INN 2.5 mg.
Acitrin-L ® is a preparation of Levocetirizine Dihydrochloride. Levocetirizine is the active (Levo) isomer of Cetirizine. It has an affinity for the human H 1 -receptor 2-fold higher than that of Cetirizine. It is a new highly effective and well tolerated non-sedating antihistamine with potent antiallergic properties.
Route: Oral
Adults and children >6 years:
One Acitrin-L ® tablet (5 mg) once daily.
Oral solution:
Renal & Hepatic impairment:
Alcohol and central nervous system depressants enhance somnolence and cognitive impairment; theophylline decreases levocetirizine clearance; ritonavir increases systemic exposure.
The use of Levocetirizine is contraindicated in patients with known hypersensitivity to Levocetirizine or any of its ingredients, or to Cetirizine. Observed reactions range from urticaria to anaphylaxis. It is also contraindicated in patients with end-stage renal disease (CL CR < 10 mL/min) and patients undergoing hemodialysis and children with impaired renal function.
Less Common: Headache, dry mouth, fatigue. Rare: Skin rash.
Overdose
Symptoms of overdose may include drowsiness in adults and initially agitation and restlessness, followed by drowsiness in children. There is no known specific antidote to Levocetirizine. In case of overdose occurrence, symptomatic or supportive treatment is recommended. Levocetirizine is not effectively removed by dialysis, and dialysis will be ineffective unless a dialyzable agent has been concomitantly ingested.
Category B. Safety in pregnancy has not been established; use only if potential maternal benefits clearly outweigh fetal risks. Lactation: Levocetirizine passes into breast milk; discontinue nursing or discontinue drug.
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of the reach of children.